Thursday 16 October, 2025
Introduction: Plasmodium vivax, one of the five species of malaria parasites that infect humans, puts approximately 2.5 billion people at risk…
Read morePoster: Drug/Disease Modelling - Infection
An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a.
Thursday 16 October, 2025
Objectives: In line with guidance to FDA to expand the use of trial simulations to support drug development [1], a…
Read morePopulation Pharmacokinetics of Anidulafungin in ICU patients
Thursday 16 October, 2025
Objectives: Anidulafungin (ANF), an echinocandin-class antifungal, is considered to be initial therapy for invasive candidiasis. Although echinocandins have shown an…
Read moreBounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections
Thursday 16 October, 2025
Objectives: A Bounded Integer [1,2] modeling approach can be used to model ordered categorical data when the number of categories becomes…
Read moreTurn-over model characterizing effect of colistin on serum-creatinine in critically ill patients
Thursday 16 October, 2025
Objectives: In the randomized clinical trial AIDA [1], surviving patients experienced Acute Kidney Injury (AKI, as measured by the RIFLE…
Read moreOptimizing treatment of cephalosporin-resistant pneumococcal meningitis
Thursday 16 October, 2025
Introduction: Bacterial meningitis is a life-threatening condition associated with a high mortality. In adults, Streptococcus pneumoniae remains the most common…
Read morePharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections
Thursday 16 October, 2025
Objectives: Chronic lung infections can be challenging to treat with conventional antibiotic dose regimens due to formation of microbial biofilms…
Read morePopulation pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis
Thursday 16 October, 2025
Objectives: Cycloserine is a bacteriostatic anti-tuberculosis drug used in combination for the treatment of multidrug-resistant tuberculosis (MDR-TB). Cycloserine remains a ‘second-line’…
Read moreModel-based analysis of the treatment window in passive cutaneous anaphylaxis mouse model applying an optimized study design
Thursday 16 October, 2025
Introduction: Passive cutaneous anaphylaxis (PCA) is a type 1 hypersensitivity reaction induced by an exogenous effect and is used as…
Read morePopulation Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia
Thursday 16 October, 2025
Objectives: Severe pneumonia is one of the most infections among critically ill patients, associated with a high mortality rate. Sitafloxacin…
Read more